In our study, we developed a signature comprising 14 PCD-related genes (BCL2A1, CASP3, CLTB, CTSK, CYP1B1, ICAM1, MMP9, PTPN2, RAC2, S100A9, TEX264, TNFAIP3, VDAC1, and ZKSCAN3) and demonstrated its ability to predict overall survival in GBM patients. The gene discussed is RAC2; the disease is glioblastoma.